What is the translation of " 的严重不良事件 " in English?

• serious adverse events
• severe adverse events

Examples of using 的严重不良事件 in Chinese and their translations into English

KD025耐受性良好，没有出现与药物相关的严重不良事件。
KD025 was well tolerated, with no drug-related serious adverse events.

研究中无患者死亡或危及生命的严重不良事件（SAEs）。
There were no deaths or life-threatening serious adverse events(SAEs).

辐射、需要镇静或麻醉以及造影剂潜在的严重不良事件是进行研究的主要障碍。
Radiation, need for sedation or anesthesia and potential serious adverse events of some of the contrast agents are major hurdles to carrying out these studies.

在接种疫苗后的头30天内没有发现可归因于疫苗的严重不良事件。
No severe adverse events attributable to the vaccine were noted 30 days after vaccination.

在HAVEN3项研究中，未发现与Hemlibra有关的严重不良事件(AEs)，且最常见的AEs与先前的研究一致。
There were no unexpected or serious adverse events(AEs) related to Hemlibra, and the most common AEs were consistent with previous studies.

在Sangamo的SB-728-T临床试验中没有发现SB-728-T产品相关的严重不良事件，并且没有观察到抗锌指核酸酶抗体的发展。
No SB-728-T product-related serious adverse events were reported in Sangamo's SB-728-T clinical trials, and there was no observation of development of anti-zinc finger nuclease antibodies.

在接种疫苗后的头30天内没有发现可归因于疫苗的严重不良事件。
No severe adverse events attributable to the vaccine were noted in the first 30 days after vaccination.

总的来说，接种疫苗似乎不增加疾病活动，并且不造成患者的严重不良事件。
Overall, vaccinations do not appear to increase the disease activity and do not cause severe adverse events in patients.

研究中没有报告与药物相关的严重不良事件，Ampreloxetine的耐受性良好。
There were no drug-related serious adverse events reported, and ampreloxetine was generally well tolerated in the study.

疫苗接种耐受性良好，无与治疗相关的严重不良事件（SAES）。
Well-tolerated and without any vaccine related serious adverse events(SAEs).

此外，VK5211在本研究中表现出良好的安全性和耐受性，没有与药物有关的严重不良事件（SAE）报告.
In addition, VK5211 demonstrated encouraging safety and tolerability in this study, with no drug-related serious adverse events(SAEs) reported.

USPSTF没有发现与孕妇戒烟行为干预有关的任何严重不良事件。
The USPSTF did not find any serious adverse events related to behavioral interventions for smoking cessation in pregnant women.

在这项研究中，没有报告与治疗有关的严重不良事件或死亡。
In this study, no treatment-related serious adverse events or deaths were reported.

研究的主要目的是评估与设备或程序相关的严重不良事件的发生率。
The primary endpoint of the study was to evaluate the incidence of device or procedure related serious adverse events.

没有观察到剂量限制毒性，也没有归因于治疗的严重不良事件。
No dose-limiting toxicities have been observed, and no serious adverse events have been attributed to the therapy.

联合治疗组没有观察到新的安全性信号，两个治疗组的严重不良事件均为不常见。
No new safety signals were observed in the combination treatment, and serious adverse events were uncommon in both treatment groups.

此外，VK5211在本研究中表现出良好的安全性和耐受性，没有与药物有关的严重不良事件（SAE）报告.
VK5211 demonstrated encouraging safety and tolerability in this study, with no drug-related serious adverse events reported.

在这项研究中，没有报告与治疗有关的严重不良事件或死亡。
In the study there were no treatment-related serious adverse events or deaths were reported.

只有28名（1％）参与者报告了与研究治疗相关的严重不良事件。
Only 28(1%) participants reported study-treatment-related serious adverse events.”.

虽然没有人对治疗产生反应，但没有与治疗相关的严重不良事件。
While none responded to the therapy, there were no treatment-related serious adverse events.

纳入的研究中（短期至中期，至多2年），没有与电子香烟有关的严重不良事件报告。
None of the included studies(short- to mid- term, up to two years) detected serious adverse events considered possibly related to electronic cigarette use.

在接受Ofev治疗的患者中，最常见的严重不良事件是肺炎（Ofev组2.8%vs安慰剂组0.3%）。
The most frequent serious adverse event reported in patients treated with Ofev was pneumonia( 2.8% Ofev versus 0.3% placebo).

总的来说，3%的严重不良事件与研究药物有关，少数严重不良事件（1%）导致研究药物停用。
In total, 3% of SAEs were related to the study medication with few SAEs(1%) leading to discontinuation of study medication.

临床数据表明，两项研究中经历治疗相关的严重不良事件的患者均不到10%(单药治疗组为9.8％，联合治疗组为8.7％)。
Fewer than 10% of patients in both studies reported treatment-related serious adverse events(9.8% in the monotherapy arm and 8.7% in the combination arm).

两种治疗方案的严重不良事件（≥3级）的总发生率相似，并观察到某些特定副作用的发生率存在一定差异.
The overall rate of severe adverse events(≥grade 3) was similar between both therapies, with differences observed in the incidence of certain side effects.

根据秋水仙碱的严重不良事件(AE)报道，发生肺炎的风险有所增加，基于21事件和9事件(0.9%比0.4%，P=0.03)。
There was an increased risk of pneumonia reported as a serious adverse event(AE) with colchicine based on 21 versus 9 events(0.9% vs 0.4%, P=0.03).

最常见的严重不良事件为感染。
The most common serious adverse events were serious infections.

最常见的严重不良事件为感染。
The most common serious adverse reactions were serious infections.